BTIG On Exact Sciences: Final Task Force Stance Could Lead To Routine Reimbursement More Quickly

Loading...
Loading...

EXACT Sciences Corporation EXAS shares spiked 34 percent on June 14, following a JAMA [The Journal of the American Medical Association] article meant for release on June 21 being leaked. BTIG’s Sean Lavin maintained a Buy rating for the company, with a price target of $9. The analyst believes that the shares could move higher as more investors discover the article.

If the JAMA article is published and reflects updated recommendations of the USPSTF [US Preventive Services Task Force], the guidelines would help EXACT Sciences obtain routine reimbursement faster than the company may have under the previous recommendation. “While the update is not a perfect result, we see it as a major positive for the company,” analyst Sean Lavin wrote.

New Guidelines

The older USPSTF recommendation was less positive and resulted in shares declining from ~$18 to below $10. Although the USPSTF is yet to issue a formal recommendation, the leaked JAMA article states that the USPSTF highly recommends colon cancer screening between ages 50 and 75, but would no longer rank tests; instead, provide a list of acceptable ones that includes FITDNA, or Cologuard.

“While this seems like a bailout by the Task Force and we wonder why it is so reluctant to strongly recommend other tests vs. colonoscopy (relationships would not stun us), we believe being put on par with colonoscopy will help EXAS gain routine reimbursement and more rapid adoption,” Lavin commented.

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorLong IdeasReiterationAnalyst RatingsTrading IdeasbtigSean Lavin
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...